Wednesday, July 8, 2026

pharma · Schizophrenia · Bipolar I Disorder · LBRX

LB PHARMACEUTICALS

LB PHARMACEUTICALS clinical programs — 2 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

New York, USA HQ
2015 Founded
36 Employees
Public company Type
LBRX · NYSE Ticker
Company details
Status
Public
HQ
New York, USA
Founded
2015
Employees
36
Programs
3
Drugs
1
Patents
7
Intelligence · Clinical Programs

LB PHARMACEUTICALS projects

2 ClinicalTrials.gov programs sponsored by LB PHARMACEUTICALS.

LB PHARMACEUTICALS has 2 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. LB-102

    LB PHARMACEUTICALS INC

    Schizophrenia

    phase 3 small molecule active

    4 trials
  2. LB-102 (50 mg tablet)

    LB PHARMACEUTICALS INC

    Schizophrenia

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does LB PHARMACEUTICALS have?

2 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.